Wednesday, June 29, 2022
No Result
View All Result
Medical Finance
  • Home
  • News
  • Interviews
  • Mediknowledge
  • Insights From Industry
  • Thought Leaders
  • Coronavirus
  • Whitepapers
  • Home
  • News
  • Interviews
  • Mediknowledge
  • Insights From Industry
  • Thought Leaders
  • Coronavirus
  • Whitepapers
No Result
View All Result
Medical Finance
No Result
View All Result
Home Coronavirus

T-cell and neutralizing antibody response after a third COVID-19 vaccine dose in hemodialysis patients

by Medical Finance
in Coronavirus
Study: Severe Acute Respiratory Coronavirus-2 Antibody and T cell response after a third vaccine dose in hemodialysis patients compared with healthy controls. Image Credit: ainata / Shutterstock.com
9
SHARES
99
VIEWS
Share on FacebookShare on Twitter

The current coronavirus disease 2019 (COVID-19) pandemic, which is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has resulted in a significant impact on global health. In most individuals, SARS-CoV-2 infection only causes mild disease; however, in a small minority of patients, COVID-19 can lead to severe respiratory failure and death.

Study: Severe Acute Respiratory Coronavirus-2 Antibody and T cell response after a third vaccine dose in hemodialysis patients compared with healthy controls. Image Credit: ainata / Shutterstock.com

Study: Severe Acute Respiratory Coronavirus-2 Antibody and T cell response after a third vaccine dose in hemodialysis patients compared with healthy controls. Image Credit: ainata / Shutterstock.com

Background

Severe disease and increased risk of death associated with COVID-19 are observed in patients undergoing hemodialysis (HD). As a result, HD patients are among those prioritized to receive COVID-19 vaccinations.

Previous research has highlighted that HD patients elicit a diminished immune response after two doses of a COVID-19 vaccine. Although some research has tried to expand the understanding on this area, the T-cell interferon- γ (IFF-γ) response in HD patients following immunization has not been fully described. Due to the reduction of vaccine-induced antibodies and the rise of COVID-19 cases in Austria, the third dose of COVID-19 vaccines has been advised.

In a recent study published on the medRxiv* preprint server, researchers compare the impact of a third messenger ribonucleic acid (mRNA) COVID-19 vaccine in HD patients to healthy controls by measuring antibody levels and IFN-γ responses six to eight weeks after these individuals had received their third dose. Using this information, the authors were interested in establishing differences between the groups and determining whether further safeguards are required to appropriately protect this vulnerable population.

Patient flowchart. This flowchart is a graphical representation of the study design. The time axis on the left shows various significant time points in the study for easy orientation. The column beside the time points lists the events that occurred at this time point. Entries in this column are explained in the box at the bottom right of the flowchart.

Patient flowchart. This flowchart is a graphical representation of the study design. The time axis on the left shows various significant time points in the study for easy orientation. The column beside the time points lists the events that occurred at this time point. Entries in this column are explained in the box at the bottom right of the flowchart.

About the study

The current prospective cohort study evaluated the antibody and IFN-γ response to two doses of the Pfizer/BioNTech BNT-162b2 mRNA vaccine followed by a booster mRNA vaccine dose. The eligibility criteria for HD patients included dialysis treatment for at least three months and receipt of a Comirnaty vaccine. The healthy control group consisted of volunteer healthcare workers who had received the same vaccinations as the HD patients.

Initially, 81 dialysis patients were invited to receive a third booster vaccine dose. Four of these individuals became infected with SARS-CoV-2, two were unable to be vaccinated due to high C-reactive protein (CRP) levels, three obtained a transplant, and 12 died. Finally, a total of 60 HD patients were included in the study to receive their third vaccine dose.

Comparatively, a total of 65 healthy people were included as controls in the current study.

Study findings

Antibody titers against the SARS-CoV-2 receptor-binding domain (RBD) in 65 healthcare workers and 60 HD patients were assessed. Six to eight weeks after receiving a third COVID-19 vaccine dose, 100% of the control group had neutralizing antibody titers exceeding 15 BAU/ml. After the third vaccine dose, 97% of HD patients seroconverted.

No significant difference was observed in the SARS-CoV-2 RBD-specific antibody titers when the control group was compared to the HD patient group six to eight weeks following the third dose. However, HD patients with low initial antibody titers or who were considered non-responders had considerably lower antibody titers after receiving their third vaccine dose than the control and HD patient responder groups.

IFN-γ titers that were greater than the cut-off level were observed in 96% of the healthcare workers and 76% of the HD patients. Thus, the distribution of IFN-γ secretion differs between the three groups. The only significant difference was observed in median IFN-γ quantile regression analysis of the control group as compared to previously low/non-responder HD patients.

Reports of adverse events (AE) between the two groups were evaluated and compared descriptively, with all data obtained through self-reported questionnaires. To this end, no participants in either of the groups reported AEs that required hospitalization or a visit to an emergency department. In comparison to HD patients, the control group reported more local and systemic AEs after receiving their third vaccine dose.

Systemic adverse events (AEs) after the third vaccination. All numbers represent the percentages of dialysis (n = 36) and control (n = 61) patients. The AEs were recorded using a standardized questionnaire and graded by the patients (Grade 1: mild, does not interfere with activity; Grade 2: moderate, interferes with activity; Grade 3: severe, prevents daily activity). No Grade 4 events (emergency department visits or hospitalization) were reported. HD patients, patients on hemodialysis; GI, gastrointestinal AEs (diarrhea, nausea and vomiting).

Systemic adverse events (AEs) after the third vaccination. All numbers represent the percentages of dialysis (n = 36) and control (n = 61) patients. The AEs were recorded using a standardized questionnaire and graded by the patients (Grade 1: mild, does not interfere with activity; Grade 2: moderate, interferes with activity; Grade 3: severe, prevents daily activity). No Grade 4 events (emergency department visits or hospitalization) were reported. HD patients, patients on hemodialysis; GI, gastrointestinal AEs (diarrhea, nausea and vomiting).

Implications

Taken together, the current study findings indicate that the third dose of a COVID-19 vaccine is a viable method for improving immune responses in most HD patients to levels comparable to healthy controls. To prevent HD patients from severe SARS-CoV-2 infection, more research on alternate immunization techniques should be conducted in the future.

*Important notice

bioRxiv publishes preliminary scientific reports that are not peer-reviewed and, therefore, should not be regarded as conclusive, guide clinical practice/health-related behavior, or treated as established information

Total
0
Shares
Share 0
Tweet 0
Pin it 0
Share 0
Medical Finance

Medical Finance

Related Posts

Study: Identifying SARS-CoV-2 regional introductions and transmission clusters in real time. Image Credit: Dotted Yeti/Shutterstock

Researchers develop a website to identify SARS-CoV-2 regional clusters in real-time

by Medical Finance
June 28, 2022
0

In a recent study posted to the medRxiv* pre-print server, a team of researchers developed a phylogenetics-based website to identify...

Study: Milk From Women Diagnosed With COVID-19 Does Not Contain SARS-CoV-2 RNA but Has Persistent Levels of SARS-CoV-2-Specific IgA Antibodies. Image Credit: sasaton krungsee/Shutterstock

Analyzing milk produced after maternal COVID-19 diagnosis for the presence of SARS-CoV-2

by Medical Finance
June 29, 2022
0

The coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), led to the implementation...

Study: Potential Associations Between Microbiome and COVID-19. Image Credit: Rost9/Shutterstock

Microbial characteristics of COVID-19

by Medical Finance
June 29, 2022
0

The coronavirus disease 2019 (COVID-19) pandemic, triggered by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has caused over...

Study: Prevalence and determinants of persistent symptoms after infection with SARS-CoV-2: Protocol for an observational cohort study (LongCOVID-study). Image Credit: Starocean/Shutterstock

Prevalence of persistent Long COVID symptoms after SARS-CoV-2 infection

by Medical Finance
June 28, 2022
0

In a recent pre-print study posted to the medRxiv* pre-print server, a team of researchers assessed the prevalence, risk factors,...

Study: Molecular basis of SARS-CoV-2 Omicron variant receptor engagement and antibody evasion and neutralization. Image Credit: natatravel/Shutterstock

Exploring the structural basis of antibody evasion and enhanced transmission of the SARS-CoV-2 Omicron variant

by Medical Finance
June 28, 2022
0

In a study recently posted to the biorxiv* pre-print server, researchers used cryogenic electron microscopy (cryo-EM) analysis to capture the open and...

Study: Plasma SARS-CoV-2 RNA levels as a biomarker of lower respiratory tract SARS-CoV-2 infection in critically ill patients with COVID-19. Image Credit: CROCOTHERY/Shutterstock

Plasma SARS-CoV-2 viral RNA as a valuable biomarker for SARS-CoV-2 infection in the lungs

by Medical Finance
June 28, 2022
0

In a recent study posted to the medRxiv* preprint server, researchers evaluated plasma and lower respiratory tract (LRT) severe acute...

Next Post
Study: Human Galectin-9 Potently Enhances SARS-CoV-2 Replication and Inflammation In Airway Epithelial Cells. Image Credit: Corona Borealis Studio / Shutterstock.com

Researchers investigate Galectin-9 as a new treatment target for COVID-19

Study: Risk of Myocarditis and Pericarditis Following BNT162b2 and mRNA-1273 COVID-19 Vaccination. Image Credit: Teeradej / Shutterstock.com

Study evaluates risk estimates of myocarditis and pericarditis from mRNA-1273 and BNT162b2 vaccines

0 0 votes
Article Rating
Subscribe
Login
Notify of
guest
guest
0 Comments
Inline Feedbacks
View all comments

Support

  • Contact
  • Disclaimer
  • Home
  • Privacy Policy
  • Terms And Conditions

Categories

  • Coronavirus
  • Insights From Industry
  • Interviews
  • Mediknowledge
  • News
  • Thought Leaders
  • Whitepapers

More News

  • Study: Anti-SARS-CoV-2 swine glyco-humanized polyclonal antibody XAV-19 retains neutralizing activity against SARS-CoV-2 B.1.1.529 (Omicron). Image Credit: Design_Cells/Shutterstock
    Assessing the neutralizing ability of polyclonal antibody XAV-19 against SARS-CoV-2 Omicron variant
  • By Anamaria Mejia a60125ebe2694f9e8eabf0159ee2c5ff 620x480
    Chemically modified rocaglates have a stronger effect against viral replication
  • Home
  • Privacy Policy
  • Contact
  • Disclaimer
  • Terms And Conditions

© 2022 Medical Finance - Latest Financial and Business News

No Result
View All Result
  • Interviews
  • Mediknowledge
  • News
  • Insights From Industry
  • Coronavirus
  • Thought Leaders
  • Whitepapers
wpDiscuz
0
0
Would love your thoughts, please comment.x
()
x
| Reply